1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Lilly Acquires Sigilon

M&A Deal Summary

Lilly Acquires Sigilon

On June 29, 2023, Lilly acquired life science company Sigilon for 310M EUR

Acquisition Highlights
  • This is Lilly’s 23rd transaction in the Life Science sector.
  • This is Lilly’s 12th largest (disclosed) transaction.
  • This is Lilly’s 26th transaction in the United States.
  • This is Lilly’s 7th transaction in Massachusetts.

M&A Deal Summary
Date 2023-06-29
Target Sigilon
Sector Life Science
Buyer(s) Lilly
Deal Type Add-on Acquisition
Deal Value 310M EUR
Advisor(s) Lazard
Canaccord Genuity (Financial)
Ropes & Gray (Legal)

Target

Sigilon

Cambridge, Massachusetts, United States
Sigilon is a biopharmaceutical company that develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. Sigilon was formed in 2015 and is based in Cambridge, Massachusetts.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 45.0B USD (2024)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. The company's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 30 of 38
Sector: Life Science M&A 23 of 31
Type: Add-on Acquisition M&A Deals 23 of 30
State: Massachusetts M&A 7 of 9
Country: United States M&A 26 of 33
Year: 2023 M&A 2 of 5
Size (of disclosed) 12 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-20 DICE

South San Francisco, California, United States

DICE designs and develops oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. DICE was founded in 2013 and is based in South San Francisco, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-14 Versanis

New York, New York, United States

Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The company's lead asset, bimagrumab, is being advanced in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Versanis was founded in 2021 and is based in New York, New York.

Buy $1.9B
Mergr

Solution for

Product

Company

Legal